| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Depreciation | - | 0 |
| Operating lease right-of-use asset and liability, net | -1,790 | -1,193 |
| Net cash used in operating activities | -11,632,743 | -9,065,316 |
| Proceeds from issuance of convertible promissory notes | 5,714,800 | 5,714,800 |
| Proceeds from issuance of shares of common stock and warrants | 6,396,888 | 4,057,719 |
| Proceeds from exercise of pre-funded warrants | 154 | - |
| Issuance costs | 440,213 | 336,255 |
| Net cash provided by financing activities | 11,671,629 | 9,436,264 |
| Net increase (decrease) in cash and cash equivalents | 38,886 | 370,948 |
| Cash and cash equivalents at beginning of period | 5,786,753 | - |
| Cash and cash equivalents at end of period | 5,825,639 | - |
Indaptus Therapeutics, Inc. (INDP)
Indaptus Therapeutics, Inc. (INDP)